Autolus Therapeutics (6A3A) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6A3A Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Autolus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6A3A Stock 12 Month Forecast

Average Price Target

€6.65

▲(222.60% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is €6.65 with a high forecast of €8.63 and a low forecast of €4.32. The average price target represents a 222.60% change from the last price of €2.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.6306,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.645562,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.5100461538461536,3.0200923076923076,3.5301384615384617,4.040184615384615,4.550230769230769,5.060276923076923,5.570323076923077,6.0803692307692305,6.590415384615384,7.100461538461538,7.610507692307692,8.120553846153847,{"y":8.6306,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.357350923076923,2.7147018461538464,3.072052769230769,3.4294036923076923,3.7867546153846154,4.144105538461538,4.501456461538462,4.8588073846153845,5.216158307692307,5.573509230769231,5.930860153846154,6.288211076923076,{"y":6.645562,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.1781,2.3562,2.5343,2.7123999999999997,2.8905,3.0686,3.2466999999999997,3.4248,3.6029,3.7809999999999997,3.9591,4.1372,{"y":4.3153,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.589,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.319,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€8.63

Average Price Target€6.65

Lowest Price Target€4.32

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€4.32

Buy

109.48%

Upside

Assigned

08/12/26

Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)

Gil Blum

Needham

€8.63

Buy

318.96%

Upside

Reiterated

08/11/26

Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory

Emily Bodnar

H.C. Wainwright

€8.63

Buy

318.96%

Upside

Reiterated

08/11/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rajan Sharma

Goldman Sachs

€4.66→€5.01

Buy

143.00%

Upside

Assigned

08/11/26

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (NASDAQ: ODTX), Metagenomi, Inc. (NASDAQ: MGX) and Autolus Therapeutics (NASDAQ: AUTL)

Salim Syed

Mizuho Securities

€8.63

Buy

318.96%

Upside

Reiterated

06/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL), Galmed Pharmaceuticals (NASDAQ: GLMD) and Oculis Holding (NASDAQ: OCS)

Asthika Goonewardene

Truist Financial

€8.63→€6.9

Buy

235.17%

Upside

Reiterated

01/13/26

Truist Financial Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€4.32

Buy

109.48%

Upside

Assigned

08/12/26

Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)

Gil Blum

Needham

€8.63

Buy

318.96%

Upside

Reiterated

08/11/26

Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory

Emily Bodnar

H.C. Wainwright

€8.63

Buy

318.96%

Upside

Reiterated

08/11/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rajan Sharma

Goldman Sachs

€4.66→€5.01

Buy

143.00%

Upside

Assigned

08/11/26

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (NASDAQ: ODTX), Metagenomi, Inc. (NASDAQ: MGX) and Autolus Therapeutics (NASDAQ: AUTL)

Salim Syed

Mizuho Securities

€8.63

Buy

318.96%

Upside

Reiterated

06/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL), Galmed Pharmaceuticals (NASDAQ: GLMD) and Oculis Holding (NASDAQ: OCS)

Asthika Goonewardene

Truist Financial

€8.63→€6.9

Buy

235.17%

Upside

Reiterated

01/13/26

Truist Financial Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARWRArrowhead Pharmaceuticals

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

AXGNAxoGen

HITIHigh Tide

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Autolus Therapeutics

3 Months

Matt PhippsWilliam Blair

Success Rate

18/38 ratings generated profit

Average Return

+1.76%

Copying Matt Phipps's trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +1.76% per trade.

1 Year

Gil BlumNeedham

Success Rate

17/32 ratings generated profit

Average Return

+6.62%

Copying Gil Blum's trades and holding each position for 1 Year would result in 53.13% of your transactions generating a profit, with an average return of +6.62% per trade.

2 Years

Gil BlumNeedham

Success Rate

14/32 ratings generated profit

Average Return

-13.36%

Copying Gil Blum's trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of -13.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6A3A Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6A3A has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6A3A average Analyst price target in the past 3 months is 6.65.

Each month's total comprises the sum of three months' worth of ratings.

6A3A Financial Forecast

6A3A Earnings Forecast

Next quarter’s earnings estimate for 6A3A is -€0.14 with a range of -€0.17 to -€0.09. The previous quarter’s EPS was -€0.13. 6A3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6A3A has Performed in-line its overall industry.

6A3A Sales Forecast

Next quarter’s sales forecast for 6A3A is €34.50M with a range of €31.60M to €39.71M. The previous quarter’s sales results were €39.51M. 6A3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6A3A has Performed in-line its overall industry.

6A3A Stock Forecast FAQ

What is DE:6A3A’s average 12-month price target, according to analysts?

Based on analyst ratings, Autolus Therapeutics Plc’s 12-month average price target is 6.65.

What is DE:6A3A’s upside potential, based on the analysts’ average price target?

Autolus Therapeutics Plc has 222.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Autolus Therapeutics Plc a Buy, Sell or Hold?

Autolus Therapeutics Plc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Autolus Therapeutics Plc’s share price target?

The average share price target for Autolus Therapeutics Plc is 6.65. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €8.63 ,and the lowest forecast is €4.32. The average share price target represents 222.60% Increase from the current price of €2.06.

What do analysts say about Autolus Therapeutics Plc?

Autolus Therapeutics Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Autolus Therapeutics Plc?

To buy shares of DE:6A3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Autolus Therapeutics (6A3A) Stock Forecast & Price Target

6A3A Analyst Ratings

6A3A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Autolus Therapeutics

6A3A Analyst Recommendation Trends

6A3A Financial Forecast

6A3A Earnings Forecast

6A3A Sales Forecast

6A3A Stock Forecast FAQ

Detailed List of Analyst Forecasts